ATE399538T1 - Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen - Google Patents

Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen

Info

Publication number
ATE399538T1
ATE399538T1 AT04723523T AT04723523T ATE399538T1 AT E399538 T1 ATE399538 T1 AT E399538T1 AT 04723523 T AT04723523 T AT 04723523T AT 04723523 T AT04723523 T AT 04723523T AT E399538 T1 ATE399538 T1 AT E399538T1
Authority
AT
Austria
Prior art keywords
polymer
polyethylene
ethylene
matrix composition
styrene
Prior art date
Application number
AT04723523T
Other languages
English (en)
Inventor
Gina Fischer
Daniel Bar-Shalom
Lillian Slot
Anne-Marie Lademann
Original Assignee
Egalet As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2003/000765 external-priority patent/WO2004041252A1/en
Application filed by Egalet As filed Critical Egalet As
Application granted granted Critical
Publication of ATE399538T1 publication Critical patent/ATE399538T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04723523T 2003-03-26 2004-03-26 Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen ATE399538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300464 2003-03-26
PCT/DK2003/000765 WO2004041252A1 (en) 2002-11-08 2003-11-07 Controlled release carvedilol compositions

Publications (1)

Publication Number Publication Date
ATE399538T1 true ATE399538T1 (de) 2008-07-15

Family

ID=33099580

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08158752T ATE454886T1 (de) 2003-03-26 2004-03-26 Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
AT04723523T ATE399538T1 (de) 2003-03-26 2004-03-26 Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08158752T ATE454886T1 (de) 2003-03-26 2004-03-26 Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen

Country Status (9)

Country Link
US (2) US8298581B2 (de)
EP (3) EP1610768B1 (de)
JP (1) JP4989217B2 (de)
AT (2) ATE454886T1 (de)
CA (1) CA2520312C (de)
DE (2) DE602004025159D1 (de)
DK (1) DK1610768T3 (de)
ES (1) ES2307003T3 (de)
WO (1) WO2004084869A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533531B2 (ja) * 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1429744A1 (de) * 2001-09-21 2004-06-23 Egalet A/S Polymeres freigabungssystem mit morphin
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1562552A1 (de) * 2002-11-08 2005-08-17 Egalet A/S Zusammensetzung zur kontrollierten wirkstoffabgabe von carvedilol
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US9198865B2 (en) * 2006-01-19 2015-12-01 Dow Global Technologies Llc Biologically active composition comprising ethylcellulose
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
KR100932613B1 (ko) * 2007-04-27 2009-12-17 한남대학교 산학협력단 고분자 용융공정을 이용한 약물전달용 생체적합성 고분자나노 미립구의 제조방법 및 그 나노 미립구
EP2155167A2 (de) 2007-06-04 2010-02-24 Egalet A/S Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
US7940978B2 (en) * 2007-06-05 2011-05-10 General Electric Company Automatic characterization of cellular motion
US8501230B2 (en) * 2007-12-03 2013-08-06 Trilogic Pharma Llc Self solidifying bioerodible barrier implant
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US20110250274A1 (en) * 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010088911A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
EP2515942B1 (de) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutische polymernanopartikelzusammensetzungen mit hoher glasübergangstemperatur oder copolymeren von hohem molekulargewicht
WO2011113436A1 (en) 2010-03-15 2011-09-22 Ferrosan Medical Devices A/S A method for promotion of hemostasis and/or wound healing
WO2011153334A2 (en) 2010-06-04 2011-12-08 Trilogic Pharma Llc Bioadhesive compositions for epithelial drug delivery
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
US20150056300A1 (en) * 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
KR101775727B1 (ko) 2010-12-15 2017-09-19 가톨릭대학교 산학협력단 폴리알킬렌글리콜-링커-폴리에스터 공중합체, 그 제조방법 및 용도
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
TWI641396B (zh) 2011-09-23 2018-11-21 Bvw控股公司 醫療共聚物
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
US20130225625A1 (en) * 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
EP2838512B1 (de) 2012-04-18 2018-08-22 Grünenthal GmbH Fälschungssichere und dose dumping sichere pharmazeutische darreichungsform
KR101455901B1 (ko) * 2012-05-04 2014-11-03 성균관대학교산학협력단 세레콕시브 및 폴록사머를 포함하는 공융 혼합물
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
EP3003279A1 (de) 2013-05-29 2016-04-13 Grünenthal GmbH Manipulationssichere darreichungsform mit einem oder mehreren partikeln
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6390873B2 (ja) 2013-06-21 2018-09-19 フェッローサン メディカル ディバイス エー／エス 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
WO2015044415A1 (en) * 2013-09-30 2015-04-02 Universiteit Gent Polyurethanes as oral drug delivery platform
US10350232B1 (en) 2013-11-04 2019-07-16 Peter D. Jaillet Medicinal drops
EP3073994A1 (de) 2013-11-26 2016-10-05 Grünenthal GmbH Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels kryogenen mahlens
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
WO2015091352A1 (en) 2013-12-16 2015-06-25 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EP4299058A3 (de) 2014-06-24 2024-03-27 The Trustees of Princeton University Verfahren zum einkapseln von löslichen biologika, therapeutika und kontrastmitteln
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
US10182993B2 (en) * 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
JP6087026B1 (ja) * 2015-04-07 2017-03-01 日本合成化学工業株式会社 樹脂組成物及びそれを用いた多層構造体、並びにロングラン安定性改善方法
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3302382A4 (de) * 2015-05-29 2019-02-20 Allergan, Inc. Implantat zur behandlung eines augenleidens
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
EP3135272A1 (de) * 2015-08-31 2017-03-01 Basf S.A. Zusammensetzungen für ein mundspülmittel in tablettenform
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
EP3386481A1 (de) * 2015-12-08 2018-10-17 Dow Global Technologies Llc Zusammensetzungen mit celluloseether und wasserlöslichen veresterten celluloseethern
EP3184104B1 (de) 2015-12-23 2018-09-12 Hexal AG Pharmazeutische zusammensetzung von vortioxetin-hydrobromid mit vortioxetinhydrobromid in einer polyethylenoxidmatrix
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
WO2019090030A1 (en) 2017-11-03 2019-05-09 Prudhomme Robert K Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
EP4321182A3 (de) 2018-05-09 2024-05-29 Ferrosan Medical Devices A/S Verfahren zur herstellung einer hämostatischen zusammensetzung
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
KR102538853B1 (ko) * 2019-10-30 2023-06-01 주식회사 에이디 할로이사이트 펠릿을 페로몬 흡수소재로 사용한 페로몬 방출기 및 그 제조방법
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN114796135B (zh) * 2022-03-29 2023-04-07 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
US20250064435A1 (en) * 2023-08-23 2025-02-27 Jes Tougaard Gram Method For Cell Treatment
US20250295592A1 (en) * 2024-03-20 2025-09-25 Jes Tougaard Gram Method for Controlled Release Oral Drug Delivery

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430684A (en) 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
JPS5518694B2 (de) 1973-04-02 1980-05-21
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3320583A1 (de) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
AU591171B2 (en) 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
US4844984A (en) 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
JPH0246008B2 (ja) 1984-06-01 1990-10-12 Takada Seiyaku Kk Nifuejipinjizokuseiseizainoseizohoho
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
IE59066B1 (en) 1985-02-19 1993-12-15 Key Pharma Controlled release potassium chloride
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
ES2054333T3 (es) 1989-01-30 1994-08-01 Alza Corp Forma de dosificacion para administrar un antagonista del calcio.
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
GB9025372D0 (en) 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
JPH07100191A (ja) 1993-10-06 1995-04-18 Daikyo Yakuhin Kogyo Kk 徐放性坐剤
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
AU1806895A (en) 1994-02-23 1995-09-11 Bm Research A/S Controlled release composition
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
JP3161278B2 (ja) 1995-04-26 2001-04-25 株式会社村田製作所 誘電体磁器組成物
EP0908181B8 (de) 1996-05-20 2009-04-15 Otsuka Pharmaceutical Co., Ltd. Heilmittel fuer rosazea
DE59702733D1 (de) 1996-08-15 2001-01-11 Losan Pharma Gmbh Gut schluckbare orale arzneiform
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
JP4533531B2 (ja) 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
US6395299B1 (en) * 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6534085B1 (en) * 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
JP4310010B2 (ja) * 1999-10-08 2009-08-05 パナソニック株式会社 単位電池
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6378165B1 (en) * 2000-02-17 2002-04-30 Emerson Electric Co. Pull handle with interlocking mounting mechanism for wet/dry vacuum appliance
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
WO2002065834A2 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
IN191028B (de) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
DE10131272B4 (de) * 2001-06-28 2006-03-30 Koenig & Bauer Ag Wendevorrichtung
EP1429744A1 (de) 2001-09-21 2004-06-23 Egalet A/S Polymeres freigabungssystem mit morphin
WO2003024426A1 (en) 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
EP1562552A1 (de) * 2002-11-08 2005-08-17 Egalet A/S Zusammensetzung zur kontrollierten wirkstoffabgabe von carvedilol
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2004084868A1 (en) * 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
CA2533165A1 (en) 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
US8389008B2 (en) 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
EP1732513A2 (de) 2003-12-31 2006-12-20 Alpharma, Inc. Formulierungen von rosiglitazon
CA2611081C (en) 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium

Also Published As

Publication number Publication date
JP4989217B2 (ja) 2012-08-01
US20100166866A1 (en) 2010-07-01
US20070042044A1 (en) 2007-02-22
EP1974726A3 (de) 2008-11-05
EP2186510B1 (de) 2013-07-10
ATE454886T1 (de) 2010-01-15
JP2006521301A (ja) 2006-09-21
ES2307003T3 (es) 2008-11-16
EP1610768B1 (de) 2008-07-02
US8298581B2 (en) 2012-10-30
EP2186510A3 (de) 2010-06-09
WO2004084869A1 (en) 2004-10-07
DE602004025159D1 (de) 2010-03-04
CA2520312C (en) 2013-06-18
EP1974726B1 (de) 2010-01-13
EP2186510A2 (de) 2010-05-19
DE602004014747D1 (de) 2008-08-14
DK1610768T3 (da) 2008-09-22
EP1610768A1 (de) 2006-01-04
EP1974726A2 (de) 2008-10-01
CA2520312A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE399538T1 (de) Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
Lee et al. Polymeric protein delivery systems
CA2815568C (en) Method and system for forming a pharmaceutical product directly onto a packaging surface
ATE495732T1 (de) Morphin-system mit kontrollierter freisetzung
CN105579494B (zh) 有机硅-聚醚共聚物、包含其的粘合剂和医用制品及其制备方法
CN100356908C (zh) 具有非自聚集一致不均匀性的薄膜及由其制造的给药系统
CN1098009A (zh) 用于在皮肤表面或透过皮肤表面传送药物的可挤压组合物
JPH04504515A (ja) 通気性バッキング
EP2716284A3 (de) Polyethylenoxidbasierte Folien und daraus hergestellte Arzneimittelabgabesysteme
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
CN1142400A (zh) 有结构的封闭敷裹
CA2969466A1 (en) Linear polysaccharide based film products
US20110166240A1 (en) Ph modulated films for delivery of actives
CN101321511A (zh) 递送活性剂的局部用薄膜组合物
CN102665762A (zh) 膜状药物剂型
CN102892815B (zh) 熔体挤出的膜
EP0481600A2 (de) Zur Verwendung in Human- und Tiermedizin geeignete Materialien
WO2016123696A1 (en) Oral dosage film exhibiting enhanced mucosal penetration
US7910641B2 (en) PH modulated films for delivery of actives
CN102821754B (zh) 多层熔融挤出膜
CN101005833A (zh) 具有半透明保护膜的透皮药物递送装置
US8298572B2 (en) Adhesive pharmaceutical preparation containing bisoprolol
CN108601827A (zh) 免疫诱导促进用组合物和疫苗药物组合物
US20090297585A1 (en) pH Modulated Films for Delivery of Actives
Khokhlenkova Prospects of using biopolymeric films in medicine and pharmacy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1610768

Country of ref document: EP